Journal Mobile Options
Table of Contents
Vol. 82, No. 3, 2009
Issue release date: May 2009
Urol Int 2009;82:312–317

Aurora-A/STK-15 Is Differentially Expressed in the Micropapillary Variant of Bladder Cancer

Compérat E. · Roupret M. · Conort P. · Chartier-Kastler E. · Bitker M.-O. · Richard F. · Capron F. · Haertig A. · Cussenot O. · Camparo P.
aService d’Anatomie et Cytologie Pathologique, Hôpital La Pitié Salpêtrière, and bService d’Urologie, Hôpital La Pitié Salpêtrière et Hôpital Tenon, CHU-Est, Université Pierre et Marie Curie, and cService d’Anatomie et Cytologie Pathologique, Hôpital des Instructions des Armées Val-de-Grâce, Paris, France

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Introduction: Micropapillary carcinoma (MPC) of the bladder is a rare and aggressive histologic variant of urothelial carcinoma (UC). At the time of presentation, most MPC are muscle invasive with frequent vascular invasion (VI). Our series explores protein expression of markers known to be indicators of poor clinical outcome and progression, trying to explain aggressiveness of MPC. Patients and Methods: 18 patients with MPC were reviewed. We explored protein expression of p53, MIB-1, Aurora-A and survivin in MPC and compared their expression to conventional urothelial carcinoma (CUC) of the same grade and stage. Results: Patients, aged 46–85 years, underwent transurethral resection or cystoprostatectomy for UC. MPC was either pure (39%) or only partially present (61%). 55% of the patients died. VI was seen in 95%. MPC displayed overexpression of p53 and MIB-1, Aurora-A and survivin. No statistically significant difference could be made with CUC except for Aurora-A (p = 0.03). Conclusions: This is the first study to explore different markers of bad clinical outcome in MPC. We suggest that Aurora-A via mechanisms implied into early steps of mitosis might play a role in aggressive clinical behavior of MPC.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Amin MB, Ro JY, el-Sharkawy T, Lee KM, Troncoso P, Silva EG, et al: Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma. Am J Surg Pathol 1994;18:1224–1232.
  2. Johansson SL, Borghede G, Holmang S: Micropapillary bladder carcinoma: a clinicopathological study of 20 cases. J Urol 1999;161:1798–1802.
  3. Comperat E, Camparo P, Haus R, Chartier-Kastler E, Radenen B, Richard F, et al: Aurora-A/STK-15 is a predictive factor for recurrent behaviour in non-invasive bladder carcinoma: a study of 128 cases of non-invasive neoplasms. Virchows Arch 2007;450:419–424.
  4. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y: Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol 2007;177:481–487.
  5. Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y: Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res 2006;12:7369–7373.
  6. Fraizer GC, Diaz MF, Lee IL, Grossman HB, Sen S: Aurora-A/STK15/BTAK enhances chromosomal instability in bladder cancer cells. Int J Oncol 2004;25:1631–1639.
  7. Yamamoto Y, Matsuyama H, Kawauchi S, Furuya T, Liu XP, Ikemoto K, et al: Biological characteristics in bladder cancer depend on the type of genetic instability. Clin Cancer Res 2006;12:2752–2758.
  8. Sen S, Zhou H, Zhang RD, Yoon DS, Vakar-Lopez F, Ito S, et al: Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 2002;94:1320–1329.
  9. Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y: Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 2007;109:1106–1113.
  10. Litlekalsoy J, Vatne V, Hostmark JG, Laerum OD: Immunohistochemical markers in urinary bladder carcinomas from paraffin-embedded archival tissue after storage for 5–70 years. BJU Int 2007;99:1013–1019.
  11. Eble JN SG, Epstein JI, Sesterhenn IA: WHO Classification of Tumors. Tumors of the Genitourinary and Male Genital Organs. V. Lyon, IARC Press, 2004.
  12. Fromont G, Roupret M, Amira N, Sibony M, Vallancien G, Validire P, et al: Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma. Eur Urol 2005;48:764–770.
  13. Kamat AM, Dinney CP, Gee JR, Grossman HB, Siefker-Radtke AO, Tamboli P, et al: Micropapillary bladder cancer: a review of the University of Texas M.D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 2007;110:62–67.
  14. Schultz IJ, Kiemeney LA, Roelofs R, Van Aarssen Y, Babjuk M, Willems JL, et al: The prognostic role of the STK15 T91A polymorphism and of STK15 mRNA expression in patients with urothelial cell carcinoma. Anticancer Res 2007;27:1025–1030.
  15. Schultz IJ, Kiemeney LA, Witjes JA, Schalken JA, Willems JL, Swinkels DW, et al: Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res 2003;23:3327–3331.
  16. Maranchie JK, Bouyounes BT, Zhang PL, O’Donnell MA, Summerhayes IC, DeWolf WC: Clinical and pathological characteristics of micropapillary transitional cell carcinoma: a highly aggressive variant. J Urol 2000;163:748–751.
  17. Frank I, Cheville JC, Blute ML, Lohse CM, Karnes RJ, Weaver AL, et al: Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement. Cancer 2004;101:1803–1808.
  18. Shariat SF, Karakiewicz PI, Palapattu GS, Amiel GE, Lotan Y, Rogers CG, et al: Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res 2006;12:6663–6676.
  19. Perez-Montiel D, Wakely PE, Hes O, Michal M, Suster S: High-grade urothelial carcinoma of the renal pelvis: clinicopathologic study of 108 cases with emphasis on unusual morphologic variants. Mod Pathol 2006;19:494–503.
  20. Kamat AM, Gee JR, Dinney CP, Grossman HB, Swanson DA, Millikan RE, et al: The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol 2006;175:881–885.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50